You just read:

CytoSorbents Awarded Approximately $1.0 Million in Phase II SBIR Funding to Optimize New Treatment Approaches for Severe Hyperkalemia

News provided by

CytoSorbents Corporation

Nov 01, 2017, 07:05 ET